Classical mycosis fungoides is the most common type of mycosis fungoides (MF), a form of cutaneous T-cell lymphoma, and is characterized by slow progression from patches to more infiltrated plaques an...
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
The documentation surrounding mycosis fungoides is limited primarily due to its rarity and the complexity of its clinical presentation. As a form of cutaneous T-cell lymphoma, it affects a small patient population, making systematic studies challenging. Moreover, the variability in symptoms and progression complicates the establishment of a comprehensive clinical profile.
To navigate your care for mycosis fungoides, consider consulting a hematologist or oncologist with specific expertise in cutaneous T-cell lymphomas. It is also beneficial to explore participation in clinical trials, which may provide access to emerging therapies. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer valuable information and support. While there are currently no identified patient organizations specifically for mycosis fungoides, engaging with broader lymphoma support groups may also be helpful.
There are several orphan drugs associated with mycosis fungoides, including FDA-approved treatments such as brentuximab vedotin and meclorethamine. Additionally, there are drugs in development, including a human anti-CD4 monoclonal antibody and MRG-106, an oligonucleotide inhibitor of microRNA miR-155-5p. Currently, there are 61 active clinical trials exploring various treatment options for this condition. For more information, you can search the active trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=mycosis%20fungoides.
Actionable guidance for navigating care for mycosis fungoides
To navigate your care for mycosis fungoides, consider consulting a hematologist or oncologist with specific expertise in cutaneous T-cell lymphomas. It is also beneficial to explore participation in clinical trials, which may provide access to emerging therapies. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer valuable information and support. While there are currently no identified patient organizations specifically for mycosis fungoides, engaging with broader lymphoma support groups may also be helpful.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 23 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning mycosis fungoides
Updated Feb 9, 2026
A case series explores the management of mycosis fungoides using chlormethine hydrochloride gel alongside systemic therapies. The findings contribute to understanding treatment combinations for this rare skin lymphoma.
A phase 2 trial evaluated resminostat as a maintenance treatment for patients with advanced-stage mycosis fungoides or Sézary syndrome. The study was multicenter, double-blind, and randomized, providing insights into the drug's efficacy in this rare skin lymphoma.